SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana (CVNA) is trending with high volatility after its earnings report missed adjusted profit estimates despite record revenue, fueling intense community debate around its business model, heavy reliance on loan sales, and perceived accounting practices amid a lack of clear forward guidance.

TOSHI

TOSHI is actively discussed as the community observes bullish charting patterns and increasing volume, signaling potential for a breakout amidst a broader altcoin season, with many highlighting its role as the "face of Base" within the Coinbase ecosystem.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending due to a significant after-hours rally following its mixed Q4 earnings, where the stock surged despite missing revenue and EPS estimates but provided a strong outlook for Q1 Marketplace GOV. This has sparked a heated debate, with bulls cheering the unexpected rebound and growth prospects, while bears remain skeptical, citing valuation and the earnings misses.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings is generating buzz from a $10 million statement of work for its qSpeed-Mine cryptocurrency acceleration platform and a strategic agreement with SaverOne to develop an RF-based defense platform. Community conversation also highlights recent institutional interest, including a significant stake from Goldman Sachs, positioning the low-float stock for potential upside across its AI, defense, and autonomous systems portfolio.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to recent conditional marketing authorization for its bladder cancer drug Anktiva across 33 European countries, alongside earlier approval in Saudi Arabia for both bladder and lung cancer. This global expansion, highlighted by Dr. Patrick Soon-Shiong's active communication about further international growth and hiring, fuels strong community discussion about the drug's broad potential, substantial short interest, and the increasing pressure on bears as the company's valuation rises.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amidst community debate over a recent Delaware court ruling favoring Commave in a lawsuit, which some fear could lead to "nine-figure" remedies and highlights ongoing frustration with management's perceived ethics. This legal setback is, however, being met with strong speculation of an imminent acquisition following a key board appointment with M&A expertise, while investors also await European approval for MIPLYFFA and long-term data, despite persistent frustration over the stock's valuation and perceived manipulation.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending due to a significant and sustained downturn, reaching new 52-week lows amidst investor frustration and confusion. The community is actively debating whether the stock has found a bottom, pointing to recent leadership changes, a weaker outlook, and broader macroeconomic concerns affecting pet spending, all while anticipating the upcoming March earnings report for a potential catalyst.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending after announcing its acquisition of Kodiak Building Partners, a move the community sees as a significant step in Brad Jacobs' ambitious strategy to consolidate and transform the building materials distribution industry, fueling expectations for further M&A activity and long-term growth.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending heavily ahead of its anticipated earnings report, which follows its recent crossing of a trillion-dollar market capitalization. Community discussion is sharply divided, with bulls highlighting strong e-commerce and resilient consumer demand for value, while bears focus on its unusually high price-to-earnings ratio and potential for a correction.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending after securing Medicare coverage for its NeXT Personal MRD test in lung cancer, a pivotal milestone that the community sees as validating its ultra-sensitive technology and accelerating revenue potential in the rapidly expanding precision oncology market. Investors are closely watching for additional reimbursement approvals, anticipating significant long-term growth and a re-rating of the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.

CONMED (NYSE:CNMD) Upgraded to Hold at Zacks Research

Zacks Research raised CONMED from a "strong sell" rating to a "hold" rating in a report on Tuesday...

CONMED Corporation (NYSE:CNMD) Receives Consensus Recommendation of "Reduce" from Analysts

Shares of CONMED Corporation (NYSE:CNMD - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the eight ratings firms that are currently covering the firm, Marketbeat...

CONMED (NYSE:CNMD) Reaches New 12-Month Low - Should You Sell?

CONMED (NYSE:CNMD) Reaches New 52-Week Low - Here's What Happened...

CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up

CNMD posts strong fourth-quarter 2025 results with EPS and revenue beat, driven by surgical growth and improved gross margin.

CONMED (NYSE:CNMD) Given New $42.00 Price Target at Wells Fargo & Company

Wells Fargo & Company lifted their target price on CONMED from $41.00 to $42.00 and gave the stock an "equal weight" rating in a research report on Thursday...

Needham & Company LLC Reiterates Hold Rating for CONMED (NYSE:CNMD)

Needham & Company LLC reaffirmed a "hold" rating on shares of CONMED in a report on Thursday...

CONMED Q4 Earnings Call Highlights

CONMED (NYSE:CNMD) reported fourth-quarter fiscal 2025 sales of $373.2 million, representing a 7.9% year-over-year increase as reported and 7.1% growth in constant currency, as management emphasized...

Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CONMED (CNMD) Q4 2025 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

Conmed Corp.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $WMT earnings on Thursday?

CNMD
Conmed Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CNMD News

CNMDConmed Corp.